India's vaccination rates remain sluggish; the number of daily Covid-19 tests has also waned considerably as the country faces an imminent threat from the Omicron variant.
The public health expert avers that pharma companies, the Government, and regulatory authorities acted quickly together, from bringing vaccine technology to vaccinating over 100 crore Indians.
Once we're able to revive and re-establish the business, we can look at diversification, Sanjeev Kumar Bijli, joint managing director, PVR, told Fortune India.
While the Reserve Bank of India kept policy rates and its accommodative stance unchanged, additional monetary measures have been brought in to fight the second wave of Covid-19.
The recent surge in Covid-19 infections, the central bank says, adds uncertainty to the outlook on domestic growth as restrictions could dampen demand improvement and delay the return of normalcy.
Aided by strong demand recovery, credit ratio rebounds to 1.33 in H2FY21, from 0.54 in H1FY21. GDP could grow at 11% in FY22, but the resurgence in Covid-19 cases is a key downside risk, says CRISIL.
In the context of vaccination, effective communication should deliver clarity around who, when, where, and how much the vaccine will cost. And India's vaccine deployment can be a great case study.
Despite the Survey’s positive tone, the Sensex and Nifty 50 closed in the red, falling nearly 8% in a matter of five trading sessions from their January 21 life–high.
